The continuous renal replacement therapy market is expected to increase from USD 1,214.6 billion in 2023 to USD 2,771.6 billion in 2033. The market is likely to capture an 8.6% CAGR during the forecast period.
Market Technological Advances to Improve Kidney Disease Management
Technological advancements in CRRT informed RRT dose and the application of sophisticated modalities have accelerated the treatment of AKI in critically sick patients. Such breakthroughs have significantly enlarged the field of extracorporeal therapy in the ICU. Furthermore, software integration is anticipated to become a new tool for enhanced equipment. Allowing CRRT treatments to be performed more efficiently and safely.
Integrating bioimpedance with online hematocrit data has an impact on therapy delivery and online hemodynamic stability. The incorporation of thermal energy balance aid in the monitoring of the patient's blood temperature. This enables a precise energy balance to be accomplished by changing the dialysate based on temperature sensors installed on blood and dialysate lines.
Integrated care is supported by technology such as data collecting, personalized advice delivery, and outcome measurement. As a result, implementing innovative software solutions aid in the treatment of acute renal injury and organ failure in critically ill patients.
| Report Attribute | Details |
|---|---|
| Continuous Renal Replacement Therapy Market Value (2023) | USD 1,214.6 billion |
| Continuous Renal Replacement Therapy Market Anticipated Value (2033) | USD 2,771.6 billion |
| Continuous Renal Replacement Therapy Market Growth Rate (2023 to 2033) | 8.6% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The continuous renal replacement therapy market accounted for USD 1,127.0 billion in 2022, expanding at an 8.3% CAGR from 2018 to 2022.
Continuous renal replacement therapy (CRRT) is a prominent treatment option for critically ill patients with acute kidney injury (AKI). Particularly in hemodynamically unstable individuals. It includes the removal of solutes from blood using hemodialysis, hemofiltration, or a combination of the two procedures.
CRRT therapy is often administered in an ICU for roughly 24 hours, as opposed to other types of traditional renal replacement therapies. Such as intermittent hemodialysis (IHD), which is administered for 4 to 6 hours or less.
Leading acute treatment manufacturers are implementing crucial methods such as technical progress to improve dialysis care. For example, in 2019, Baxter International Inc. cleared their Pris Max system and integrated Ther Max blood warmer for continuous renal replacement therapy and therapeutic plasma exchange (TPE).
Factors such as the increasing prevalence of acute renal injury worldwide, the rising incidence of sepsis, and ICU patients enhance the market.
| Historical CAGR (2018 to 2022) | 8.3% |
|---|---|
| Forecast CAGR (2023 to 2033) | 8.6% |
As per the FMI analysts, a valuation of USD 2,771.6 billion by 2033 end is estimated for the market.
| 2016 | USD 681.75 billion |
|---|---|
| 2021 | USD 1,029.85 billion |
| 2022 | USD 1,127.0 billion |
| 2023 | USD 1,214.6 billion |
| 2033 | USD 2,771.6 billion |
The key risk factors for acute kidney damage include diabetes, hypertension, and an aging population. Diabetes is becoming increasingly common over the world. As a result, as the prevalence of diabetes rises, so does the count of patients suffering from acute renal injury.
Increased knowledge among healthcare providers may lessen its occurrence and enhance the management of the underlying disorders in the elderly population.
As the global incidence of AKI and AKF rises, the demand for continuous renal replacement therapy is predicted to rise. According to the International Society of Nephrology (INR), 13.3 million cases of AKI are reported worldwide each year. This is expected to accelerate the use of continuous renal replacement treatment.
The prevalence of kidney-related illnesses is expected to skyrocket as the world's old population expands. This, in turn, is likely to drive significant expansion in the continuous renal replacement treatment market throughout the forecast period.
If left untreated, this condition can cause renal failure or kidney damage. As well as end-stage renal disease, increasing demand for renal replacement treatment. As a result, the rising prevalence of acute and chronic renal illnesses is expected to drive market growth.
Principal Consultant
Leading industry companies, including Baxter International Inc., Fresenius Kabi, and Medtronic, are investing in Research and development activities. Aiming to develop CRRT systems in order to effect corporate growth. Baxter, for example, has created the PRISMAFLEX critical care system.
The PRISMAFLEX system is a versatile platform that provides tailored therapies based on the patient's comfort and suitability. The equipment is outfitted with cutting-edge technology that allows for precise CRRT in patients with acute renal damage.
Furthermore, B. Braun's Diapact CRRT system is integrated with sophisticated technology. It allows the successful treatment of acute kidney injuries and disorders. The crucial blood filtering process is carried out precisely and without interruption, ensuring that patients recover quickly. Such advancements in CRRT systems, together with innovation, result in increased adoption of CRRT systems.
The populace in developing countries is price-sensitive, they favor lower-cost products. Although the cost of continuous renal replacement therapy in developing nations is high-priced. Therefore, a huge percentage of the population cannot afford it due to poor purchasing power. This reduces the demand for the adoption of continuous renal replacement therapy in both developing and developed countries.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Continuous renal replacement therapy (CRRT) is a highly sophisticated and important therapy that necessitates extensive nursing care. Continuous assessment of indications, vascular access, minimizing unnecessary interruptions, and limiting problems all require properly educated ICU nurses. Although, the shortage of licensed nurses in ICU settings may further stymie market expansion.
Companies that manufacture continuous renal replacement treatment products in North America face many regulatory impediments. As a result, the FDA's complicated requirements, reduce demand for these goods.
In Europe, for example, CRRT is allowed for a variety of indications. This includes cardiac failure, liver support, intoxication, increased Intracranial Pressure (ICP), rhabdomyolysis, and post-cardiac surgery.
In North America, no CRRT machine has been approved by the FDA for the treatment of several diseases. Similarly, no anticoagulant drug for blood infusion during a CRRT operation has been approved by the FDA so far, despite being licensed in Europe.
Several CRRT drugs that have been approved in other countries have yet to be approved by the FDA in North America due to these stringent regulatory restrictions. The presence of tight regulatory standards for the approval of new CRRT product launches in this region is impeding market growth.
Rising demand for CRRT treatments, radical innovation in systems, and rising frequency of renal disorders are propelling this market in North America.
Emerging markets such as China, India, Brazil, and Mexico are likely to provide considerable growth potential for the market participants. AKI was observed in 17.3 cases per 1,000 individuals in India. According to a study conducted on 100 critically sick patients in a prospective observational study published in the Journal of Clinical and Diagnostic Research (JCDR) 2018.
To capitalize on the considerable growth potential in emerging markets, firms are increasingly focused on strategic developments. To enhance their presence in these markets and allow them to reach many clients.
Because of the increased demand from AKI patients, key players in the CRRT market are focusing on creating novel product lines. These firms are working hard to provide low-cost CRRT systems in the Asian market. According to the WHO, renal dialysis is generally available in 60% of nations globally.
Furthermore, due to less onerous data requirements, regulatory rules in the Asia Pacific area are more adaptable and business-friendly. This, combined with increased competition in developed countries (Europe, Japan, and Australia), drives manufacturers of continuous renal replacement treatment products to concentrate on emerging regions.
CRRT consumables include hemofilter, line sets, fluid/dialysate, and accessories. Haemofilters, often known as artificial kidneys, are made of a hollow fiber membrane that controls the amount of solute and fluid evacuated.
Businesses such as Baxter and Fresenius offer a variety of consumables across modalities for patients with severe renal diseases. Despite their low cost, these products are more frequently purchased than those in other segments. As a result, the consumables segment is expected to grow at an 8.9% annual rate.
The continuous renal replacement treatment market has been divided by end users into hospitals, clinics, and others. The hospital segment dominated the market in 2018 and continues to do so over the forecast period.
The growth in critically sick patients around the world is leading to an increase in patient admissions to ICUs in hospitals. Furthermore, an increase in hospitals worldwide is predicted to help the segment's growth. Top-tier facilities with continuous renal replacement therapy systems in ICUs around the world drive the segment.
In addition, patient preference for hospitals is propelling the segment. In emerging economies, the existence of many hospitals, well-equipped infrastructure, the use of technologically advanced products, and favorable healthcare insurance policies are expected to drive the segment during the projection period.
The market report's competition section includes profiles of prominent market players based on their market shares and product offerings. Similarly, it includes distinct channel strategies, marketing initiatives, product reach, and corporate dashboards.
It is reported to be 93% available in high-income countries, whereas 46% and 27% are available in developing and under-developed countries, respectively.
Fresenius Medical Care AG & Co. KGaA, one of the world's top dialysis product and service suppliers, has introduced multi-Filtrate PRO, a Continuous Renal Replacement Therapy (CRRT) therapy system for the treatment of acute kidney failure in critically ill intensive care patients.
To expand their product reach in the Asian market, some leading producers of continuous renal replacement treatment are focused on unique marketing methods. Leading suppliers' price reduction strategy in consumables is a key success factor.
These businesses face stiff competition from local consumables providers. These supplies have a firm grip on traditional distribution channels including wholesalers and retailers.
| Attribute | Details |
|---|---|
| Market Size Value in 2023 | USD 1,214.6 billion |
| Market Size Value at End of Forecast (2033) | USD 2,771.6 billion |
| Market Analysis | USD billion for Value |
| Key Region Covered | North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA) |
| Key Segments | By Product Type, By End User, By Region |
| Key Companies Profiled | Fresenius Medical Care AG & Co. KGaA; Baxter International Inc.; B. Braun Melsungen AG; Medica SpA; Nikkiso Co.,Ltd.; Nipro corp.; Toray Medical Co., Ltd.; NxStage Medical, Inc.; Asahi Kasei Corp.; Medtronic plc. |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
The continuous renal replacement therapy market is anticipated to go up from USD 1,214.6 billion in 2023 to USD 2,771.6 billion by 2033, exhibiting a CAGR of 8.6%.
With an 8.3% CAGR between 2018 and 2022, the continuous renal replacement therapy market reached USD 1,127.0 billion in 2022.
Given its advanced healthcare infrastructure, The United States holds a leading position in the continuous renal replacement therapy market.
Key continuous renal replacement therapy market trends include a surge in home-based therapies and a heightened focus on personalized patient management.
Prominent market players such as Baxter International Inc., B. Braun Melsungen AG, Medica SpA, Nikkiso Co., Ltd., and Nipro Corp. dominate the continuous renal replacement therapy market.
1. Executive Summary | Continuous Renal Replacement Therapy Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Modality 5.1. Slow Continuous Ultrafiltration (SCUF) 5.2. Continuous Venovenous Hemofiltration (CVVHF) 5.3. Continuous Venovenous Hemodialysis (CVVHD) 5.4. Continuous Venovenous Hemodiafiltration (CVVHDF) 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 6.1. Dialysate & Replacement Fluids 6.2. Disposables 6.3. Systems 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapy 7.1. Renal 7.2. Non-renal 7.3. Combination 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. Middle East & Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. B. Braun Melsungen AG 18.2. Baxter International, Inc. 18.3. Fresenius Medical Care AG & Co. KGaA 18.4. Asahi Kasei Corporation 18.5. NIPRO Corporation 18.6. Toray Medical Co., Ltd 18.7. NxStage Medical, Inc. 18.8. Medtronic plc 18.9. Abbott 18.10. Pfizer 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Continuous Renal Replacement Therapy Market
